by Introduction:
The global Orodispersible Tablets Market is estimated to be valued at US$ 9.29 billion in 2022 and is expected to grow at a CAGR of 9.3% during the forecast period of 2023-2030, according to a report published by Coherent Market Insights.
Market Overview:
Orodispersible tablets, also known as rapidly disintegrating or melt-in-mouth tablets, are popular oral drug delivery systems that dissolve rapidly in the mouth.
Key Advantages of Orodispersible Tablets:
1. Convenience: These tablets offer a convenient dosage form, especially for individuals who have difficulty swallowing conventional tablets or capsules.
2. Enhanced Drug Absorption: The unique formulation of orodispersible tablets enables rapid dissolution and absorption of the drug, leading to faster therapeutic action.
3. Patient Compliance: They are an ideal option for pediatric, geriatric, and mentally ill patients who may have compliance issues with conventional solid oral formulations.
4. Improved Bioavailability: Orodispersible tablets help overcome certain drug absorption challenges and enhance bioavailability.
Market Key Trends:
Rapid Technological Advancements Revolutionizing Orodispersible Tablets Market
One of the key trends in the orodispersible tablets market is the rapid technological advancements in formulation and manufacturing techniques. Companies are investing in innovative technologies such as freeze-drying, lyophilization, and direct compression methods to improve the stability and manufacturability of these tablets. For instance, AstraZeneca recently launched a new orodispersible formulation of a popular antipsychotic drug, which offers improved patient compliance and better therapeutic outcomes.
Porter’s Analysis:
i. Threat of New Entrants: Low-Moderate
The orodispersible tablets market requires significant investment in research and development, formulation expertise, and manufacturing capabilities. Entry barriers are moderate due to stringent regulatory requirements, but established players have a competitive advantage.
ii. Bargaining Power of Buyers: Moderate-High
As the demand for orodispersible tablets increases, buyers gain bargaining power due to the availability of several options in the market. Buyers can negotiate pricing and demand higher quality products.
iii. Bargaining Power of Suppliers: Moderate
Suppliers of key raw materials such as active pharmaceutical ingredients (APIs) and excipients have moderate bargaining power. However, collaborations with multiple suppliers and vertical integration strategies help mitigate potential risks.
iv. Threat of New Substitutes: Low
Orodispersible tablets offer unique advantages such as convenience, rapid drug action, and improved patient compliance. The availability of substitutes with similar benefits is limited, resulting in a low threat of substitution.
v. Competitive Rivalry: High
The market is highly competitive, with key players investing in research and development to launch innovative formulations. Intense competition drives companies to differentiate their products based on factors such as taste, disintegration time, and ease of use.
Key Takeaways:
– The Global Orodispersible Tablets Market Growth is expected to grow at a CAGR of 9.3% during the forecast period, driven by increasing adoption of these tablets by patients and healthcare providers.
– Regional Analysis: North America is anticipated to dominate the orodispersible tablets market due to the presence of well-established healthcare infrastructure, high healthcare expenditure, and early adoption of advanced drug delivery systems. Asia-Pacific is expected to be the fastest-growing region, driven by improving healthcare access, rising geriatric population, and increasing focus on patient-centric drug delivery systems.
– Key Players: AstraZeneca PLC, GlaxoSmithKline PLC, Novartis International AG, Johnson & Johnson Services, Inc., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Pfizer Inc., Cipla Limited, Dr. Reddy’s Laboratories Ltd., Sun Pharmaceutical Industries Ltd., Lupin Pharmaceuticals, Inc., Torrent Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., Eisai Co., Ltd., and Takeda Pharmaceutical Company Limited are the major players operating in the global orodispersible tablets market. These companies are focusing on strategic collaborations, product innovations, and expanding their distribution networks to gain a competitive edge.
In conclusion, the orodispersible tablets market is witnessing significant growth due to the convenience, improved patient compliance, and faster therapeutic action provided by these innovative drug delivery systems. Technological advancements, regional expansion, and collaborations among key players are expected to drive market growth, improving patient outcomes and transforming healthcare delivery.
